SEC Form 10-Q filed by CVS Health Corporation
$CVS
Retail-Drug Stores and Proprietary Stores
Consumer Staples
Unavailable
Unavailable
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/13/2025 | $55.00 → $75.00 | Market Perform → Outperform | Leerink Partners |
| 2/12/2025 | Neutral → Overweight | Cantor Fitzgerald | |
| 1/30/2025 | Hold → Buy | Edward Jones | |
| 12/3/2024 | $66.00 | Hold → Buy | Deutsche Bank |
| 11/18/2024 | $60.00 → $66.00 | Equal Weight → Overweight | Wells Fargo |
| 10/10/2024 | $63.00 → $82.00 | Equal Weight → Overweight | Barclays |
| 10/4/2024 | $59.00 → $85.00 | Hold → Buy | TD Cowen |
| 5/30/2024 | $61.00 | Neutral | Robert W. Baird |
Leerink Partners upgraded CVS Health from Market Perform to Outperform and set a new price target of $75.00 from $55.00 previously
Cantor Fitzgerald upgraded CVS Health from Neutral to Overweight
Edward Jones upgraded CVS Health from Hold to Buy